Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Cancer Res. 2020 Dec 22;27(5):1463–1475. doi: 10.1158/1078-0432.CCR-20-3555

Figure 2. Tarloxotinib-E inhibits proliferation of cell lines harboring EGFR, HER2, or NRG1 oncogenes.

Figure 2.

Dose response curves of cell proliferation of A) CUTO14, CUTO17, and CUTO18 (EGFR ex20ins); B) H1781 (HER2 ex20ins), H2170 and Calu-3 (HER2 amp) and C) MDA-MB-175VIII (breast cancer, DOC4-NRG1 fusion) and H661 (HER4 overexpression). Cells were treated with tarloxotinib (prodrug) or tarloxotinib-E (active drug) for 72 hours and analyzed by MTS assay. Experiments were done in triplicate; mean ± SEM is plotted.